Join Growin Stock Community!

Omeros corporationOMER.US Overview

US StockHealthcare
(No presentation for OMER)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

OMER AI Insights

OMER Overall Performance

OMER AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OMER Recent Performance

-0.33%

Omeros corporation

0.05%

Avg of Sector

-0.31%

S&P500

OMER PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

OMER Key Information

OMER Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

OMER Profile

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Price of OMER

OMER FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OMER Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.71
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.93
PB Ratio
8.44
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
25.99%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.71
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.93
PB Ratio
8.44
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
25.99%
3-Year Profit Growth
25.99%

  • When is OMER's latest earnings report released?

    The most recent financial report for Omeros corporation (OMER) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OMER's short-term business performance and financial health. For the latest updates on OMER's earnings releases, visit this page regularly.

  • How much debt does OMER have?

    As of the end of the reporting period, Omeros corporation (OMER) had total debt of 363.44M, with a debt ratio of 1.96. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does OMER have?

    At the end of the period, Omeros corporation (OMER) held Total Cash and Cash Equivalents of 2.4M, accounting for 0.01 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is OMER's EPS continuing to grow?

    According to the past four quarterly reports, Omeros corporation (OMER)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.47. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OMER?

    Omeros corporation (OMER)'s Free Cash Flow (FCF) for the period is -18.48M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 42.34% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of OMER?

    The latest valuation data shows Omeros corporation (OMER) has a Price-To-Earnings (PE) ratio of -3.68 and a Price/Earnings-To-Growth (PEG) ratio of -0.24. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.